CN116685599A - 多肽及其用途 - Google Patents
多肽及其用途 Download PDFInfo
- Publication number
- CN116685599A CN116685599A CN202180084231.3A CN202180084231A CN116685599A CN 116685599 A CN116685599 A CN 116685599A CN 202180084231 A CN202180084231 A CN 202180084231A CN 116685599 A CN116685599 A CN 116685599A
- Authority
- CN
- China
- Prior art keywords
- xaa
- aib
- diacid
- amide
- cntatc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125996P | 2020-12-16 | 2020-12-16 | |
| US63/125996 | 2020-12-16 | ||
| PCT/EP2021/086034 WO2022129254A1 (en) | 2020-12-16 | 2021-12-15 | Polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116685599A true CN116685599A (zh) | 2023-09-01 |
Family
ID=79287870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180084231.3A Pending CN116685599A (zh) | 2020-12-16 | 2021-12-15 | 多肽及其用途 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US12371464B2 (enExample) |
| EP (1) | EP4263586A1 (enExample) |
| JP (1) | JP7767428B2 (enExample) |
| KR (1) | KR20230120134A (enExample) |
| CN (1) | CN116685599A (enExample) |
| AR (1) | AR124391A1 (enExample) |
| AU (2) | AU2021399076B2 (enExample) |
| CA (1) | CA3204296A1 (enExample) |
| CL (1) | CL2023001719A1 (enExample) |
| CO (1) | CO2023009066A2 (enExample) |
| CR (1) | CR20230311A (enExample) |
| EC (1) | ECSP23052600A (enExample) |
| IL (1) | IL303578A (enExample) |
| MX (1) | MX2023007288A (enExample) |
| TW (1) | TW202241933A (enExample) |
| WO (1) | WO2022129254A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230120134A (ko) | 2020-12-16 | 2023-08-16 | 메디뮨 리미티드 | 폴리펩티드 및 이의 용도 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| WO2023044290A1 (en) | 2021-09-15 | 2023-03-23 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| GB2641696A (en) * | 2023-02-10 | 2025-12-10 | Hangzhou Sciwind Biosciences Co Ltd | Polypeptide and derivative thereof, composition, and use thereof |
| WO2025114501A1 (en) | 2023-11-30 | 2025-06-05 | Novo Nordisk A/S | Tri-agonists of the glp-1, gip, and amylin receptors |
| WO2025147628A2 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Dual amylin calcitonin receptor agonists |
| WO2025242620A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Polypeptide combinations and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004051014A1 (de) | 2004-10-20 | 2006-04-27 | Rwth Aachen | Chemisch modifizierte Peptidanaloga |
| CN101400698A (zh) | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| JP5703226B2 (ja) * | 2008-10-21 | 2015-04-15 | ノヴォ ノルディスク アー／エス | アミリン誘導体 |
| WO2011037970A1 (en) * | 2009-09-22 | 2011-03-31 | University Of Miami | Podocyte ph modulation and uses thereof |
| WO2013059336A1 (en) | 2011-10-18 | 2013-04-25 | Amylin Pharmaceuticals, Llc | Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties |
| CN105849123A (zh) * | 2013-12-13 | 2016-08-10 | 免疫医疗有限公司 | 蛋白酶抗性肽 |
| CN106999602B (zh) | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| CN113195524A (zh) | 2018-10-11 | 2021-07-30 | 因塔西亚治疗公司 | 人类胰淀素类似物多肽和使用方法 |
| WO2020225781A1 (en) | 2019-05-08 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate amylin agonists and uses thereof |
| KR20230120134A (ko) | 2020-12-16 | 2023-08-16 | 메디뮨 리미티드 | 폴리펩티드 및 이의 용도 |
-
2021
- 2021-12-15 KR KR1020237023385A patent/KR20230120134A/ko active Pending
- 2021-12-15 CA CA3204296A patent/CA3204296A1/en active Pending
- 2021-12-15 CR CR20230311A patent/CR20230311A/es unknown
- 2021-12-15 AU AU2021399076A patent/AU2021399076B2/en active Active
- 2021-12-15 US US17/551,701 patent/US12371464B2/en active Active
- 2021-12-15 JP JP2023536144A patent/JP7767428B2/ja active Active
- 2021-12-15 MX MX2023007288A patent/MX2023007288A/es unknown
- 2021-12-15 EP EP21839935.0A patent/EP4263586A1/en active Pending
- 2021-12-15 US US18/257,756 patent/US20240067693A1/en active Pending
- 2021-12-15 IL IL303578A patent/IL303578A/en unknown
- 2021-12-15 CN CN202180084231.3A patent/CN116685599A/zh active Pending
- 2021-12-15 WO PCT/EP2021/086034 patent/WO2022129254A1/en not_active Ceased
- 2021-12-16 TW TW110147305A patent/TW202241933A/zh unknown
- 2021-12-16 AR ARP210103535A patent/AR124391A1/es unknown
-
2023
- 2023-06-14 CL CL2023001719A patent/CL2023001719A1/es unknown
- 2023-07-06 CO CONC2023/0009066A patent/CO2023009066A2/es unknown
- 2023-07-12 EC ECSENADI202352600A patent/ECSP23052600A/es unknown
-
2024
- 2024-10-03 AU AU2024227071A patent/AU2024227071A1/en active Pending
-
2025
- 2025-02-12 US US19/052,168 patent/US20250289860A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202241933A (zh) | 2022-11-01 |
| KR20230120134A (ko) | 2023-08-16 |
| MX2023007288A (es) | 2023-07-03 |
| WO2022129254A1 (en) | 2022-06-23 |
| ECSP23052600A (es) | 2023-08-31 |
| CL2023001719A1 (es) | 2024-01-26 |
| AR124391A1 (es) | 2023-03-22 |
| CO2023009066A2 (es) | 2023-07-10 |
| JP2023554046A (ja) | 2023-12-26 |
| CA3204296A1 (en) | 2022-06-23 |
| IL303578A (en) | 2023-08-01 |
| AU2024227071A1 (en) | 2024-10-24 |
| CR20230311A (es) | 2023-09-01 |
| AU2021399076B2 (en) | 2024-07-11 |
| US20220204580A1 (en) | 2022-06-30 |
| US20240067693A1 (en) | 2024-02-29 |
| AU2021399076A1 (en) | 2023-07-27 |
| US20250289860A1 (en) | 2025-09-18 |
| AU2021399076A9 (en) | 2024-07-18 |
| EP4263586A1 (en) | 2023-10-25 |
| US12371464B2 (en) | 2025-07-29 |
| JP7767428B2 (ja) | 2025-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116685599A (zh) | 多肽及其用途 | |
| CN103596972B (zh) | 多肽 | |
| JP4148994B2 (ja) | グルカゴン様ペプチド―２アナログ | |
| CN109863168B (zh) | 胰淀素类似物 | |
| KR102824306B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| CN102197049B (zh) | 胰岛淀粉样多肽衍生物 | |
| KR20210031533A (ko) | Gip/glp1 공효능제 화합물 | |
| BR112020010244A2 (pt) | análogos de incretina e seus usos | |
| KR20200088418A (ko) | 인크레틴 유사체 및 그의 용도 | |
| JP2022509568A (ja) | 修飾されたｇｉｐペプチド類似体 | |
| KR20140043780A (ko) | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 | |
| CN102105159A (zh) | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 | |
| JP2025507323A (ja) | 生物学的安定性が向上したｇｌｐ－１およびグルカゴンの二重アゴニストペプチド | |
| IL322205A (en) | GIP/GLP1/GCG trireceptor agonists and their uses | |
| EA050089B1 (ru) | Полипептиды и варианты их применения | |
| WO2024213022A1 (zh) | 肠促胰素类似物及其制备方法和应用 | |
| EA048422B1 (ru) | Соединения-коагонисты gip/glp1 | |
| EA043950B1 (ru) | Аналоги инкретина и их применение | |
| HK1153934B (en) | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |